Strides Pharma Science Ltd (IN:STAR)
:STAR
Want to see IN:STAR full AI Analyst Report?
STAR Stock Chart & Stats
₹950.75
-₹13.60(-1.99%)
At close: 4:00 PM EST
₹950.75
-₹13.60(-1.99%)
Day’s Range― - ―
52-Week Range₹681.05 - ₹1,231.45
Previous CloseN/A
Volume639.08K
Average Volume (3M)12.54K
Market Cap
₹105.27B
Enterprise Value₹120.68B
Total Cash (Recent Filing)₹2.27B
Total Debt (Recent Filing)₹18.44B
Price to Earnings (P/E)10.3
Beta0.79
Next Earnings
Aug 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.41%
Share Statistics
EPS (TTM)43.13
Shares Outstanding92,172,714
10 Day Avg. Volume13,417
30 Day Avg. Volume12,536
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)2.40
Price to Sales (P/S)1.37
P/FCF Ratio13.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)72.63
Revenue Forecast (FY)₹56.49B
Bulls Say, Bears Say
Bulls Say
Revenue & Margin RecoveryRecent reporting shows a sustained recovery in revenue and materially improved gross and net margins, indicating better pricing, cost control and product mix. Over the next 2–6 months this supports margin sustainability, higher operating leverage and more predictable earnings power versus prior weak periods.
Free Cash Flow ConversionStrong free cash flow conversion signals durable cash generation from operations, enabling funding for working capital, maintenance capex and selective strategic investments without full reliance on external capital. This enhances financial flexibility and supports longer-term operational resilience.
Improving Return On EquityAn improved ROE and a moderate leverage profile point to better capital efficiency and shareholder value creation. This durable improvement suggests management is extracting more profit per unit of equity, supporting reinvestment capacity and providing room to manage leverage through business cycles.
Bears Say
Earnings VolatilityThe company has a history of volatile profitability including prior negative EBIT/EBITDA periods. Such structural earnings swings imply sensitivity to product approvals, competitive pricing and one-time charges, which can undermine predictability of cash flow and long-term planning over multiple quarters.
Balance Sheet ConstraintsPressure on cash balances and liability management limits financial flexibility for large investments, acquisitions or extended product launches. Persistent balance sheet constraints can increase refinancing risk and reduce the company’s ability to absorb regulatory or market setbacks over the medium term.
Free Cash Flow FluctuationsIrregular free cash flow growth and past inconsistency undermine reliable internal funding for growth, dividends or deleveraging. Structural swings in FCF tied to working capital or product cycle timing can constrain strategic initiatives and make long-term budgeting and capital allocation more difficult.
Strides Pharma Science Ltd News
STAR FAQ
What was Strides Pharma Science Ltd’s price range in the past 12 months?
Strides Pharma Science Ltd lowest stock price was ₹681.05 and its highest was ₹1231.45 in the past 12 months.
What is Strides Pharma Science Ltd’s market cap?
Strides Pharma Science Ltd’s market cap is ₹105.27B.
When is Strides Pharma Science Ltd’s upcoming earnings report date?
Strides Pharma Science Ltd’s upcoming earnings report date is Aug 05, 2026 which is in 76 days.
How were Strides Pharma Science Ltd’s earnings last quarter?
Strides Pharma Science Ltd released its earnings results on May 18, 2026. The company reported ₹13.77 earnings per share for the quarter, beating the consensus estimate of N/A by ₹13.77.
Is Strides Pharma Science Ltd overvalued?
According to Wall Street analysts Strides Pharma Science Ltd’s price is currently Overvalued.
Does Strides Pharma Science Ltd pay dividends?
Strides Pharma Science Ltd pays a Annually dividend of ₹4 which represents an annual dividend yield of 0.41%. See more information on Strides Pharma Science Ltd dividends here
What is Strides Pharma Science Ltd’s EPS estimate?
Strides Pharma Science Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Strides Pharma Science Ltd have?
Strides Pharma Science Ltd has 92,172,714 shares outstanding.
What happened to Strides Pharma Science Ltd’s price movement after its last earnings report?
Strides Pharma Science Ltd reported an EPS of ₹13.77 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.316%.
Which hedge fund is a major shareholder of Strides Pharma Science Ltd?
Currently, no hedge funds are holding shares in IN:STAR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Strides Pharma Science Ltd
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally. It operates through two segments, Pharmaceutical and Biopharmaceutical. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women's health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. Strides Pharma Science Limited was incorporated in 1990 and is headquartered in Bengaluru, India.
Technical Analysis
Alkem Laboratories Ltd.
―
Aurobindo Pharma Ltd
―
Glenmark Pharmaceuticals Limited
―
IPCA Laboratories Limited
―
Laurus Labs Ltd.
―